What does this article add to?
- This manuscript attempts to establish the efficacy and safety of
mirabegron-tamsulosin combination therapy versus the routinely used
tamsulosin alpha blocker monotherapy in a subset of Indian population
with ‘symptomatic BPH with predominantly coexisting OABS’ as a De-novo
therapeutic measure. This article is novel for its unique de-novo
utility of using mirabegron-tamsulosin combination therapy initially
from the start in medicine naive virgin select patients of ‘LUTS due
to BPH with OABS’ as opposed to the majority of published research
utilising mirabegron mainly in an add on therapy fashion to manage
residual BPH-OAB symptoms post alpha blocker therapy.
- This manuscript also especially focuses closely on investigating
whether there was of any occurrence of rising PVR and urinary
retention, associatied specifically with the concomitant use of
initial mirabegron –tamsulosin combination therapy for ‘LUTS due to
BPH with OABS’ without the add on therapy protocol as the current
literature regarding mirabegron and its effect on PVR is ambiguous
about the same.
- The current results of this research adds to the clarity in the
literature and strengthens the notion of utilizing mirabegron
combination therapy as a start-up therapy without the apparent fear of
inducing any rise in the incidence of PVR and urinary retention as
opposed to the usually employed add on protocol in majority of
patients of ‘LUTS due to BPH with OABS’. This measure in itself is
novel attempt to change the global perception of practicing urologists
towards mirabegron’s utility in the medical management of symptomatic
patients of BPH with OABS.